Insider Selling: Mesa Laboratories (NASDAQ:MLAB) CFO Sells $253,016.50 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CFO John Sakys sold 2,827 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $253,016.50. Following the transaction, the chief financial officer directly owned 19,785 shares in the company, valued at approximately $1,770,757.50. The trade was a 12.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Sakys also recently made the following trade(s):

• On Tuesday, June 16th, John Sakys sold 1,223 shares of Mesa Laboratories stock. The stock was sold at an average price of $101.27, for a total transaction of $123,853.21.

Mesa Laboratories Trading Up 1.1%

Shares of MLAB traded up $1.05 during trading hours on Tuesday, reaching $94.28. 64,805 shares of the company traded hands, compared to its average volume of 138,158. Mesa Laboratories, Inc. has a 12 month low of $55.45 and a 12 month high of $113.99. The company has a quick ratio of 1.29, a current ratio of 1.72 and a debt-to-equity ratio of 0.78. The company’s fifty day moving average price is $101.95 and its two-hundred day moving average price is $90.98. The company has a market capitalization of $520.90 million, a price-to-earnings ratio of 78.57 and a beta of 0.94.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). The company had revenue of $63.72 million during the quarter, compared to the consensus estimate of $65.21 million. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.During the same period in the previous year, the company earned ($1.31) earnings per share.

Mesa Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 15th. Stockholders of record on Friday, May 29th were given a $0.16 dividend. The ex-dividend date of this dividend was Friday, May 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.7%. Mesa Laboratories’s dividend payout ratio is currently 53.33%.

Institutional Investors Weigh In On Mesa Laboratories

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Mesa Laboratories by 5,366.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 322 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Mesa Laboratories in the 4th quarter worth approximately $27,000. Kestra Advisory Services LLC bought a new position in Mesa Laboratories during the 4th quarter valued at approximately $55,000. BNP Paribas Financial Markets raised its stake in Mesa Laboratories by 30.9% during the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 243 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Mesa Laboratories by 432.9% in the second quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock worth $79,000 after acquiring an additional 684 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Mesa Laboratories presently has a consensus rating of “Reduce” and an average target price of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.